CAR T Cell Therapy has transformed the treatment of leukemia by enabling the immune system to directly target cancer cells. In this therapy, doctors genetically modify a patient’s T cells to express a chimeric antigen receptor (CAR) that identifies specific antigens on leukemia cells and destroys them.
Despite its success, the treatment still faces major limitations. Clinical data show that more than 50% of patients eventually relapse after CAR T therapy. One key reason is that leukemia cells can reduce or completely lose the targeted antigen when exposed to therapeutic pressure. Once this occurs, CAR T cells can no longer recognize or eliminate the cancer cells effectively.
Limitations of Current Solutions
Until now, researchers have mainly tried to overcome this challenge by redesigning CAR structures through additional genetic engineering. Although this approach can improve targeting, it is often time-consuming, technically complex, and expensive. Consequently, scientists have continued searching for simpler strategies to strengthen CAR T cell performance.
Scientists Develop a Biomimetic Enhancement Strategy
Researchers from the Institute of Process Engineering of the Chinese Academy of Sciences have now developed a novel biomimetic platform that significantly enhances CAR T therapy without requiring any additional genetic modification of the CAR T cells.
As reported by medicalxpress, the research team validated the strategy in multiple mouse models of relapsed and refractory leukemia and in laboratory experiments using numerous patient-derived samples. Their findings were published in the journal Cell on March 9.
Identifying a Key Protein Target
To understand how leukemia cells evade treatment, the researchers collaborated with Zhujiang Hospital and the Institute of Hematology & Blood Diseases Hospital to analyse a large number of clinical samples.
Their investigation revealed that CD71, a protein responsible for transporting iron into cells, is highly expressed on leukemia cells across different disease types and stages. Importantly, the researchers also found that CD71 appears on autologous CAR T cells, making it a promising target for strengthening interactions between the two cell types.
Creating a Molecular Bridge Between Cells
Building on this discovery, the researchers designed a biomimetic ferritin aggregation cell engager (FACE). This structure acts as a molecular bridge that strengthens the interaction between CAR T cells and leukemia cells.
To create the platform, the team carefully controlled solvent conditions and assembly parameters to trigger the self-assembly of ferritin, the natural ligand of CD71.
During CAR T cell preparation, FACE binds strongly to CD71 on the surface of CAR T cells. After infusion into the patient, the same FACE molecules also attach to CD71 on leukemia cells. As a result, the platform physically links the two cell types and enhances the ability of CAR T cells to recognize and eliminate leukemia cells.
Improved Effectiveness With Lower Cell Doses
The researchers tested the new system in patient-derived xenograft (PDX) leukemia models. When leukemia cells expressed normal antigen levels, FACE-enhanced CAR T cells achieved the same therapeutic effect as conventional CAR T therapy using only one-fifth of the cell dose.
Furthermore, the approach significantly reduced the risk of cytokine release syndrome, a serious side effect commonly associated with CAR T therapy.
Maintaining Activity Even With Low Antigen Levels
One of the most striking findings emerged when leukemia cells expressed very low levels of the target antigen—less than 10% of normal levels. Under these conditions, traditional CAR T cells became largely ineffective.
In contrast, FACE-CAR T cells continued to eliminate leukemia cells effectively, achieving 100% survival in PDX models. This suggests that the platform may help overcome one of the major causes of treatment failure.
Drug-Loaded Platform Further Strengthens Treatment
The research team also developed an advanced version of the platform called FACED, which incorporates therapeutic drugs into the ferritin structure.
Because ferritin naturally forms a cage-like structure, it can carry drug molecules that directly target leukemia cells. The resulting FACED-CAR T cells successfully treated PDX models with high leukemia burden and low antigen expression.
Notably, the system also eliminated antigen-negative leukemia cells, which are often responsible for disease relapse after treatment.
Simple Integration Into Existing CAR T Manufacturing
According to Wei Wei, the corresponding author from the Institute of Process Engineering, the FACE platform offers a practical advantage.
“Our FACE platform is composed of an endogenous protein and FDA-approved polymer derivatives,” he explained. “It can be prepared through a simple and scalable process and integrated directly into existing CAR T manufacturing workflows as a culture supplement before infusion.”
Because the method does not require additional genetic modification, researchers believe it could be implemented in a wide range of clinical settings.
Broad Potential Across Leukemia Subtypes
Co-author Ma Guanghui emphasized the platform’s broad potential. The researchers evaluated FACE across diverse patient-derived leukemia samples and clinically relevant PDX models, demonstrating its effectiveness in multiple disease subtypes and treatment-resistant conditions.
The team also created an efficacy database and developed an AI-assisted predictive framework that can accurately forecast the therapeutic benefits of FACE-enhanced CAR T therapy.
Promising Strategy for Future Cancer Treatments
Peer reviewers at Cell described the findings as highly relevant to the CAR T field and highlighted the platform as a promising translational strategy for improving treatment outcomes in hematologic cancers.
Because the method avoids additional genetic engineering, experts believe it could be adopted more easily across clinical centres while addressing the challenge of antigen variability in leukemia.
Overall, the biomimetic FACE platform represents a practical and scalable approach to strengthening CAR T cell therapy. With strong preclinical evidence supporting its effectiveness, the strategy could help improve treatment outcomes for patients with relapsed or refractory leukemia in the future.